Single domain antibodies capable of modulating bace activity
AssigneesVib Vzw, Vrije Universiteit Brussel, Katholieke Universiteit Leuven, KU LEUVEN R&D
InventorsBart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
Life of this patent
Estimating the term…
Abstract
Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
Claims6
An isolated single domain antibody, devoid of a light chain, wherein the single domain antibody specifically binds beta secretase (BACE1) and is able to inhibit cleavage of beta amyloid precursor protein (APP) as determined in a cellular assay.
Dependencies are inferred from the claim text.